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Abstract: Morphine is a well-known μ-opioid receptor (MOR) agonist and an efficient 
analgesic, but its long-term use inevitably leads to drug addiction and tolerance. Here, we 
show that specific inhibition of β-arrestin2 with its siRNA lentivirus microinjected in 
mice periaqueductal gray matter (PAG) significantly improved both acute and chronic 
morphine analgesia and delayed the tolerance in the hotplate test. The specific effect of 
β-arrestin2 was proven by overexpression or knockdown of its homology β-arrestin1 in 
PAG, which showed no significant effects on morphine analgesia. These findings suggest 
that specific siRNA targeting β-arrestin2 may constitute a new approach to morphine 
therapy and other MOR agonist-mediated analgesia and tolerance. 
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1. Introduction 
 
Morphine has long been used as a clinical pain-relieving agent. However, the antinociceptive 
efficacy of morphine decreases over prolonged courses of treatment and long-term application of 
morphine will inevitably produce tolerance. Moreover, long-term use of morphine also leads to 
addiction. A large body of evidence has shown that stimulation of μ-opioid receptor (MOR) is not only 
one of the main mechanisms for morphine analgesia, but also the main mechanism for 
morphine-induced tolerance and addiction [1-3].   
β-Arrestins, including β-arrestin 1 and β-arrestin 2, are highly expressed in the central nervous 
system (CNS) [4] and their critical role in regulating MOR in the CNS has been demonstrated. In 
β-arrestin 2 knockout mice, the antinociceptive effects of morphine are remarkably enhanced and 
prolonged, while the tolerance to the antinociceptive effects is significantly attenuated in both hot-plate 
and tail-flick tests [5,6] with the mechanisms of desensitization of the MOR [7,8]. Coincidently, as 
MOR agonists produce antinociceptive tolerance, the expression of β-arrestin 2 is significantly 
increased in locus coeruleus, cortex and striatum [9-11], while the intrathecal administration of 
β-arrestin 2 antisenses delays the development of tolerance to morphine [12]. Thus, regulating the 
expression of β-arrestin 2 in special regions of CNS may be one approach to improve the 
antinociceptive effect of morphine and delay its tolerance.   
Morphine is known to produce analgesia by activating MOR via supraspinal and spinal-related 
pathways finally located to PAG. PAG is thus widely considered to be a main output pathway of the 
limbic system and in turn, control pain transmission [13]. Moreover, it has been reported that the 
antinociceptive effects of morphine is attenuated in rats receiving microinjections of β-arrestin 2 
adenovirus in PAG [14]. In the present study, we investigated the effects of β-arrestin 2 in mice PAG 
by locally and transiently delivering β-arrestin 2 or its specific siRNA lentiviruses on acute and chronic 
morphine-induced analgesia and tolerance.   
 
2. Results and Discussion 
 
2.1. Expression of β-arrestins mediated by lentiviruses in mouse PAG 
 
We first constructed the lentiviruses carrying human β-arrestin 1 and β-arrestin 2 or specific siRNA 
targeting mouse β-arrestin 1 or β-arrestin 2 (Figure 1a), and performed histochemical experiment and 
Western Blot analysis to determine whether microinjection of these lentiviruses in mouse PAG could 
mediate the ectopic expression of β-arrestin 1 and β-arrestin 2. As shown in Figure 1b, GFP 
fluorescence was detected in PAG of the injection site but not in the non-injection sites, and no injury 
was observed at the injection site using HE staining. And microinjection of GFP tagged β-arrestin 1 
(Arrb1-GFP) or β-arrestin 2 (Arrb2-GFP) lentivirus in PAG significantly upregulated the protein levels 
of  β-arrestin 1 and β-arrestin 2 while microinjection of GFP tagged β-arrestin 1-spcific siRNA 
(Arrb1-siRNA-GFP) or β-arrestin 2-specific siRNA (Arrb2-siRNA-GFP) clearly downregulated their 
protein levels, respectively (Figure 1c). 
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Figure 1. (a) Map of β-arrestin recombinant lentivirus generated by FUGW vector. (b) HE 
stain (left) and confocal images of the non-injection (middle) and injection site (right) in 
the PAG taken from an animal microinjected with the β-arrestin 2 lentivirus. And similar 
images of other lentiviruses used in the study were observed (data not shown). Green, GFP. 
Scale bar: 40 μm. (c) Immunoblot analysis of β-arrestin protein levels in the microinjection 
sites. β-arr1, β-arrestin 1; β-arr2, β-arrestin 2. n = 3-4 mice of each group. ***p < 0.001 
versus the GFP lentivirus. 
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2.2. Enhancement of acute and chronic morphine analgesia in mice microinjected with β-arrestin 2 
specific siRNA lentivirus in PAG 
 
The morphine-induced analgesia test was then carried out in mice microinjected with 
β-arrestin-specific siRNA lentivirus and the analgesia was evaluated by measuring response latencies 
in the hot-plate test. A dose of 10 mg/kg morphine and a route of subcutaneous administration that are 
known to induce analgesia in mice were applied. After a single administration of 10 mg/kg morphine 
subcutaneously (s.c.), the mice injected with Arrb2-siRNA-GFP lentivirus in PAG showed an 
significantly enhanced and prolonged antinociceptive response in the hotplate test compared with the 
control mice injected with WT-GFP lentivirus, with the MPE of 46% ± 7% in WT-GFP group and 64% 
± 7% in Arrb2 siRNA-GFP group at 30-45 min after morphine treatment (Figure 2a).   
 
Figure 2. (a and b) Acute morphine analgesia in mice microinjected in PAG with GFP 
tagged  β-arrestin 1-specific siRNA (Arrb1-RNAi), β-arrestin 2-specific siRNA 
(Arrb2-RNAi) or GFP control (WT) lentivirus. Mor, morphine; NS, normal saline, n = 
11-12 mice of each group. Two-way ANOVA, **p < 0.01, ***p < 0.001 versus the WT 
lentivirus mice administrated with morphine. (c) Chronic morphine analgesia in mice 
microinjected in PAG with Arrb1-RNAi, Arrb2-RNAi or WT lentivirus, n = 9-10 mice of 
each group. Two-way ANOVA, **p<0.01, ***p < 0.001 versus the WT lentivirus mice 
administrated with morphine. 
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In contrast, mice exposed to normal saline (NS) showed no significant differences between groups 
with GFP, Arrb1-siRNA-GFP or Arrb2-siRNA-GFP mice (Figure 2b), indicating that microinjection of 
β-arrestin 2 specific siRNA could only influence morphine specifically induced analgesia in this study. 
The mice microinjected with β-arrestin-specific siRNA lentivirus in PAG were also exposed to chronic 
morphine. Similar with the acute morphine treatment, the hot-plate latencies were significantly 
enhanced in Arrb2-siRNA-GFP mice for 7 days (Figure 2c) and this significance could last for 15 days 
(data not shown). However, knockdown of its homology β-arrestin 1 in mice PAG by infection with 
Arrb1-siRNA-GFP lentivirus did not show any significant differences in both acute and chronic 
morphine-induced analgesia as compared with the control mice (Figures 2a and 2c). Thus, these results 
reveal that β-arrestin 2 plays critical role in morphine analgesia in PAG differently from the roles of 
β-arrestin 1 in regulation of MOR-mediated signal transduction and opioid functions in mice PAG.   
 
2.3. Attenuation of acute and chronic morphine analgesia in mice microinjected with β-arrestin 2 
lentivirus in PAG 
 
The effect of β-arrestin 2 on morphine analgesia was also investigated in mice microinjected in 
PAG with lentiviruses carrying β-arrestin 1 or β-arrestin 2. In acute and chronic morphine treatment, 
the mice overexpressed β-arrestin 2 in PAG by infection with Arrb2-GFP lentivirus experienced a 
significantly shortened and attenuated antinociceptive response in the hotplate test compared with the 
control mice microinjected with GFP lentivirus (Figures 3a and 3c). To the contrary, microinjection of 
β-arrestin 1 lentivirus in mice PAG showed no significant changes in either acute or chronic 
morphine-induced analgesia (Figures 3a and 3c). Similar with the microinjection of siRNA lentivirus, 
mice exposed to normal saline (NS) showed no significant differences between groups with GFP, 
Arrb1-GFP and Arrb2-GFP mice (Figure 3b). Thus, these results provide further proof on the enhanced 
analgesic effects of morphine by knockdown of β-arrestin 2.   
Morphine is a classic opiate analgesic in pain treatment in conditions ranging from acute pain, 
postoperative pain to chronic pain including cancer pain [15,16]. These clinical uses of morphine are 
often required for extended periods. However, prolonged administration of morphine in chronic pain 
states often leads to antinociceptive tolerance. For obtaining the same analgesia effect, higher doses of 
the drug have to be used, resulting in serious side effects such as constipation, mental alertness 
impairment, etc. In the present study, we discovered that knockdown of β-arrestin 2 locally in PAG 
could enhance morphine analgesia and ameliorate the development of tolerance.   
It is known that morphine produces analgesic effects mainly through stimulation of MOR [1-3], 
which is desensitized by β-arrestins. β-Arrestins include β-arrestin 1 and β-arrestin 2, both of which 
are of high homology [17] and high expression in the CNS [4], but potential functional differences 
between β-arrestin 1 and β-arrestin 2 have been observed [18-20]. In the present study, we found that 
β-arrestin 1 and β-arrestin 2 differentially regulate acute and chronic morphine-induced antinociceptive 
responses. Interfering in the expression of β-arrestin 2, but not β-arrestin 1 in PAG could effectively 
mediate MOR signaling in morphine-induced analgesia. The difference may be due to the following 
reasons: 1) β-Arrestin 2 appears to be more abundant than β-arrestin 1 in CNS [4]. 2) Although both 
β-Arrestin 1 and β-arrestin 2 function as important molecules in the agonist-stimulated desensitization 
of MOR [21,22], β-arrestin 2 is more efficient than β-arrestin 1 in translocating to the membrane upon Int. J. Mol. Sci. 2009, 10                 
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stimulation of MOR [20]. Correspondingly, it has been found that acute and chronic morphine 
treatments differentially alter β-arrestin 1 and β-arrestin 2 mRNA levels in cerebral cortex, PAG, and 
locus coeruleus in rats. No significant change of β-arrestin 1 mRNA level was observed in either PAG 
or cerebral cortex following the acute or chronic morphine administration, while β-arrestin 2 mRNA 
level in these regions showed significant changes in response to morphine treatment [23], indicating 
the probable different roles of β-arrestin 1 and β-arrestin 2 in response to MOR signaling and the 
potential therapeutic application of β-arrestin 2 knockdown in the morphine  antinociceptive  tolerance.    
 
Figure 3. (a and b) Acute morphine analgesia in mice receiving PAG microinjection of 
GFP tagged β-arrestin 1 (Arrb1), β-arrestin 2 (Arrb2) or GFP control (WT) lentiviruses. 
Mor, morphine; NS, normal saline, n = 10-12 mice of each group. Two-way ANOVA, **p 
< 0.01 versus the WT lentivirus mice administrated with morphine. (c) Chronic 
morphine-induced analgesia in mice receiving PAG microinjection of Arrb1, Arrb2 or WT 
lentiviruses. n = 9-10 mice of each group. Two-way ANOVA, **p < 0.01, *p < 0.05 versus 
the WT lentivirus mice administrated with morphine. 
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β-Arrestins have been found to be ubiquitously expressed in different cells and tissues [4]. 
Considering the important role of β-arrestins in GPCR signaling [24,25], knockdown of β-arrestin 2 in 
a specific analgesia-related region may be more suitable for clinic therapy. Supraspinal regions that are 
shown to express opioid receptors and correlate to antinociception include nucleus accumbens, frontal Int. J. Mol. Sci. 2009, 10                 
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cortex, hippocampus, PAG, thalamus and hypothalamus [26,27]. PAG is extensively accepted as the 
prominent region in opioid-mediated antinociception and is found to be rich in MOR [27] Therefore, 
PAG is an ideal region for gene targeting in pain relieving therapy. Our results showed that 
knockdown of β-arrestin 2 in PAG could greatly enhance morphine-induced analgesia and delayed the 
production of tolerance, suggesting the application of the lentivirus carrying siRNA specifically 
targeting  β-arrestin 2 in PAG is a potent therapeutic strategy for morphine and other MOR 
agonists-induced antinociceptive tolerance.   
 
3. Experimental Section 
 
Mice used in this study were 3 month-old males weighing between 26 and 30 g. Experiments were 
conducted in accordance with National Institutes of Health Guide for the Care and Use of Laboratory 
Animals. Morphine sulfate was purchased from Shenyang Pharmaceutical Company, P.R. China. The 
compounds were injected at a volume about 100 μL/g animal weight.   
Human  β-arrestin 1 or β-arrestin 2 was first constructed into the vector of pIRES2-EGFP and 
further subcloned into FUGW backbone vector. Mouse β-arrestin 1 or β-arrestin 2 siRNA sequence 
from pBSU6 vector was subcloned into FUGW backbone vector. Then the FUGW plasmid encoding 
GFP, GFP tagged human β-arrestin 1 (Arrb1-GFP) or β-arrestin 2 (Arrb2-GFP), or GFP tagged 
β-arrestin 1-specific siRNA (Arrb1-siRNA-GFP) or β-arrestin 2-specific siRNA (Arrb2-siRNA-GFP, 
5’ACGTTGACATTAAGGGGCTCCC3’)  was co-transfected with packaging vectors (VsVg and PAX2) 
into HEK-293T cells to generate recombinant lentivirus. Viruses were harvested and collected to give 
the titers about 1.0×10
7 CFU/mL. For surgery and microinjection, chloral hydrate-anesthetized mice 
were positioned in a stereotaxic apparatus (NARISHIGE Scientific Instrument LAB); the lentivirus 
filled in the glass electrode was injected aiming at PAG (AP-4.5 mm; ML ±0 mm; DV 2mm). 
Lentivirus (1.5 μL) was microinjected into the PAG at a rate of 0.15 μL/min. The glass electrode was 
left in place for additional 2 min. The expression of the aim protein was detected and the behavioral 
experiment was conducted 10-13 days after virus microinjection.  
For Western Blot analysis, the brain was acutely dissected and PAG was separated in 5 minutes on 
ice. Then the section was homogenized with buffer including 50 mM Tris, 250 mM sucrose, 25 mM 
KCl and 0.5 mM PMSF. The lysates were centrifuged at 5500 × g for 10 min at 4 °C. The supernatants 
were collected and protein concentrations of the samples were determined using Micro BCA Protein 
Assay Kit (Pierce Biotechnology, Rockford, USA). Forty micrograms of protein from each sample 
were loaded on a 10% SDS-polyacrylamide gel and transferred to a nitrocellulose membrane. The 
membrane was then incubated with mouse anti-β-arrestin 1 antibody (BD Biosciences, San Jose, CA) 
and anti-β-arrestin 2 (Santa Cruz) and further incubated with secondary antibodies conjugated to 
IRDye700 (1:5,000) or IRDye800 (1:5,000). Blotted proteins were detected using the Odyssey infrared 
imaging system (Li-COR Biosciences, Lincoln, Nebraska). 
For histochemical experiment, the animals were anesthetized and perfused with NS, followed by 
iced 4% paraformaldehyde. Then the tissues were post-fixed with 4% paraformaldehyde at 4 °C for 
2-4 hrs and stored in 20% PBS-buffered sucrose solution for 36 hrs. Then frozen coronal brain sections 
(14 μm) were cut on a freezing microtome and washed by 1 × PBS for three times with each time of 5 Int. J. Mol. Sci. 2009, 10                 
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min. Then, the slices were analyzed under the fluorescence microscope (Zeiss Axio Observer Z1) or 
performed Haematoxylin-Eosin (HE) Staining. 
Hot-plate experiments were performed as described previously [5]. In each antinociception assay, 
nociceptive latencies were assessed as the response time to the hot plate. The 'response' was defined by 
the animal either licking its fore or hind paws or flicking its hind paws. In the studies, the most 
prominent response was forepaw licking and hind paw flicking. When exposed to the test under 
morphine treatment, the time limit is 30 sec to the thermal source, thus preventing prolonged painful 
stimulation and tissue damage. Such data recorded in each mouse are analyzed and presented as the 
percentage of maximum possible effect (%MPE), which is calculated by the following formula: 100% 
× [(drug response time-basal response time)/(30 sec-basal response time)] = %MPE. For acute 
antinociceptive tolerance test, antinociceptive responses were measured as hot-plate response latency 
at 52 °C after a single morphine treatment (10 mg/kg, sc). For chronic morphine treatment, mice were 
treated daily (between 13:00 and 14:00) with morphine (10 mg/kg, s.c.) and antinociception was 
assessed 30 min later on 52 °C hotplate for every day for 7 days. 
The quantitative data are represented as mean ± s.e.m., and analyzed using Sigma Stat 3.5. 
Two-way analysis of variance was used to compare differences in hot-plate latency between groups. 
 
4. Conclusions 
 
Specific inhibition of β-arrestin 2 with its siRNA lentivirus microinjected in mice PAG significantly 
improved both acute and chronic morphine analgesia and delayed the tolerance. On the contrary, 
overexpression of β-arrestin 2 in PAG of mice with its lentivirus significantly attenuated the analgesic 
effects of acute and chronic morphine. Overexpression or knockdown of β-arrestin 2 homology 
β-arrestin 1 in PAG showed no significant effects on morphine analgesia. The present findings suggest 
a new approach of specific siRNA targeting β-arrestin 2 to the therapy of morphine and other MOR 
agonists-mediated analgesia and tolerance. 
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